Dyslipidemia among HIV-infected patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India

Clinical Infectious Diseases

Volumn 52, Issue 4, 2011, Pages 540-546

  Padmapriyadarsini, Chandrasekaran ^a   Kumar, S Ramesh ^a   Terrin, Norma ^b   Narendran, Gopalan ^a   Menon, Pradeep A ^a   Ramachandran, Geetha ^a   Subramanyan, Sudha ^a   Venkatesan, Perumal ^a   Wanke, Christine ^c   Swaminathan, Soumya ^a  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISONIAZID; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRAZINAMIDE; RIFAMPICIN; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; INDIA; LIPOPROTEINS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES; TUBERCULOSIS;

EID: 79951824946     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq195     Document Type: Article

References (15)

1. Grover SA, Coupal L, Gilmore N, et al. Impact of dyslipidemia associated with highly active antiretroviral therapy on cardiovascular risk and life expectancy. Am J Cardiol 2005;95:586-91. (Pubitemid 40255245)
2. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005;6:396-402. (Pubitemid 41723307)
3. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42. (Pubitemid 46684441)
4. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile. AIDS 2001;15:2407-14. (Pubitemid 34014609)
5. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202. (Pubitemid 40741119)
6. National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
7. El Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results form a large antiretroviral naive cohort. HIV Med 2005;6:114-21. (Pubitemid 40425975)
8. van der Valk M, Kastelein J, Murphy R, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in anti atherogenic profile. AIDS 2001;15:2407-14. (Pubitemid 34014609)
9. van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003;16:19-23. (Pubitemid 36205251)
10. Wanke C, Gerrior J, Hendricks k, McNamara J, Schaefer E. Alterations in lipid profiles in HIV infected patients treated with protease inhibitor therapy are not influenced by diet. Nutr Clin Pract 2005;20:668-73. (Pubitemid 41790080)
11. Fontas E, van Leth F, Sabin A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74. (Pubitemid 38373099)
12. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV.-1. PLos Med 2004;1: e19.
13. Buchacz K, Weidle PJ, Moore D, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2008;47:304-11. (Pubitemid 351619415)
14. Das M, Pal S, Gosh A. Rural urban differences of cardiovascular disease risk factors in adult Asian Indians. Am J Hum Biol 2008;20:440-5.
15. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. 2006 revision. http://www.who.int/hiv/pub/guidelines/adult/en/.